Stryker Corporation (SYK) Stock Analysis 2026

Stryker is one of the world's largest medical device companies, specializing in orthopedic implants (hip and knee replacements), surgical equipment, neurotechnology (spine and cranial devices), and medical/surgical instruments. The company's Mako robotic-assisted surgery platform is a key growth driver — it's the leading orthopedic surgical robot with 2,500+ installations worldwide. Stryker consistently grows 8-10% annually through a combination of organic innovation and strategic acquisitions.

This chart shows how Stryker's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Stryker Corporation trades at a trailing P/E of 34.23x, generates $4.11B in free cash flow, runs a debt/equity ratio of 64.39, and converts shareholder equity into profit at a 16.5% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

28 analysts covering Stryker Corporation currently lean toward a Buy rating, with a mean 12-month price target of $382.72 (+39.1% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate SYK's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

SYK is currently in a death cross pattern, trading below its 50-day average of $328.98 and below its 200-day average of $339.56. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

SYK's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.